| Title |
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, March 2019
|
| DOI | 10.1186/s40425-019-0538-8 |
| Pubmed ID | |
| Authors |
Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta, Sandra J. Horning, Jeffrey S. Miller, Brad Kahl, Paul M. Sondel |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 43% |
| Spain | 1 | 14% |
| Greece | 1 | 14% |
| Unknown | 2 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Practitioners (doctors, other healthcare professionals) | 1 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 13% |
| Student > Doctoral Student | 3 | 7% |
| Professor | 3 | 7% |
| Student > Master | 3 | 7% |
| Student > Ph. D. Student | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 23 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 22% |
| Immunology and Microbiology | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 26 | 57% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2019.
All research outputs
#7,963,683
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,911
of 3,424 outputs
Outputs of similar age
#141,090
of 364,667 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#66
of 90 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,424 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,667 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 90 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.